Aparito is pleased to announce the appointment of Graciëlle Schutjens as Scientific Business Advisor and Director of Aparito B.V, Aparito’s Dutch entity.

Graciëlle joins Aparito following a distinguished career starting as a Clinical Research Project Manager with Quintiles (now IQVIA) before her passion for education and training saw her promoted to Training and Quality Control Manager for Europe at Parexel.

Graciëlle’s love for developing young CRAs led to her forming her own CRO in 2000 which she sold to Venn Life Sciences in 2010 where she stayed on as Chief Operating Officer to oversee an AIM listing and growth through M&A with companies throughout the UK and Europe before leaving in 2018 to work as a freelance consultant.

Graciëlle will apply her operational knowledge and expertise as Aparito grows its global customer base and maintain excellence as Aparito wins more new business facilitating decentralised and hybrid clinical trials with clients.

I need to feel a ‘click’ before I take on a challenge like this – I need to feel the energy – and I recognised myself in Elin Haf (Davies, CEO of Aparito).

The pandemic accelerated the importance of companies like Aparito and we are ahead of the companies that saw this opportunity during the pandemic; Aparito were there in time to lead this change towards more decentralised medicine and personalised healthcare.

Graciëlle Schutjens, Scientific Business Advisor and Aparito B.V. Director
Graciëlle Schutjens

I am delighted that Graciëlle has joined us. Her extensive knowledge and deep understanding of this space is second to none, and as such she brings a wealth of insight to help us grow.
Personally, I’m thrilled to be supported by a business leader in life science who’s been there already. The fact she’s a woman is a major advantage for me, too.

Dr Elin Haf Davies, CEO of Aparito

About Aparito

Aparito is a global health tech company that brings clinical trials to patients and unlocks real-world data through mobile apps, video assessments & wearable devices.

We provide innovative patient-centric clinical trials solutions that integrate specialist medical & regulatory expertise to capture patient data and develop digital endpoints for hybrid and decentralised clinical trials. 

We do all this through Atom5™, our iOS & Android-compatible web and mobile app platform. Atom5™ captures multiple, high-frequency data points from video, voice, wearables, and electronic Patient Reported Outcomes, then analyses the results in conjunction with our team of data scientists to provide rich, real-time insights to clinical teams. 

Atom5™ is regulator-friendly by design and features eConsent via a partnership with DocuSign, computer system validation and complete data privacy. The global platform operates under ISO14385 QMS and ISO/IEC 27001 ISMS accreditations and is FDA CFR21 Part 11 compliant.


Media relations

Alexander Guest – Head of Marketing, Aparito

E-Mail: alexander.guest@aparito.com Tel: +44 1978 896 191